Back to Search
Start Over
Effect of the Glucagon‐like Peptide‐1 Analogue Exenatide Extended Release in Cats with Newly Diagnosed Diabetes Mellitus
- Source :
- Journal of Veterinary Internal Medicine
- Publication Year :
- 2015
- Publisher :
- Wiley, 2015.
-
Abstract
- Background Exenatide extended release (ER) is a glucagon-like peptide-1 analogue that increases insulin secretion, inhibits glucagon secretion and induces satiation in humans with type 2 diabetes mellitus. The use of exenatide ER is safe and stimulates insulin secretion in healthy cats. Objectives The objective of this study is to assess the safety of exenatide ER and its effect on body weight, remission and metabolic control in newly diagnosed diabetic cats receiving insulin and a low-carbohydrate diet. Animals Thirty client-owned cats. Methods Prospective placebo-controlled clinical trial. Cats were treated with exenatide ER or 0.9% saline, administered SC, once weekly. Both groups received insulin glargine and a low-carbohydrate diet. Exenatide ER was administered for 16 weeks, or in cats that achieved remission it was given for 4 weeks after discontinuing insulin treatment. Nonparametric tests were used for statistical analysis. Results Cats in the exenatide ER and placebo groups had transient adverse signs including decreased appetite (60% vs. 20%, respectively, P = .06) and vomiting (53% vs. 40%, respectively, P = .715). Body weight increased significantly in the placebo group (P = .002), but not in cats receiving exenatide ER. Cats on exenatide ER achieved remission or good metabolic control in 40% or 89%, respectively, whereas in control cats percentages were 20% or 58% (P = .427 and P = .178, respectively). Conclusion and clinical importance Exenatide ER is safe in diabetic cats and does not result in weight gain. Our pilot study suggests that, should there be an additional clinically relevant beneficial effect of exenatide ER in insulin-treated cats on rate of remission and good metabolic control, it would likely approximate 20% and 30%, respectively.
- Subjects :
- Blood Glucose
Male
10253 Department of Small Animals
3400 General Veterinary
medicine.medical_treatment
Insulin Glargine
Standard Article
Cat Diseases
0403 veterinary science
Endocrinology
CATS
630 Agriculture
Glucagon secretion
04 agricultural and veterinary sciences
Incretin
10081 Institute of Veterinary Physiology
Glucagon-like peptide-1
Standard Articles
Veterinary (all)
Female
medicine.drug
medicine.medical_specialty
Remission
040301 veterinary sciences
Placebo
Metabolic control
Feline
Internal medicine
Diabetes Mellitus
Dietary Carbohydrates
medicine
Animals
Hypoglycemic Agents
General Veterinary
Venoms
Insulin glargine
business.industry
Insulin
0402 animal and dairy science
Animal Feed
040201 dairy & animal science
Hypoglycemia
Diet
Treatment
Cats
Exenatide
570 Life sciences
biology
SMALL ANIMAL
Peptides
business
Subjects
Details
- ISSN :
- 19391676 and 08916640
- Volume :
- 30
- Database :
- OpenAIRE
- Journal :
- Journal of Veterinary Internal Medicine
- Accession number :
- edsair.doi.dedup.....38d4f55a42445536c1a20daa41ecb1bc